Radiopharma CDMOs navigate supply chain, raw material challenges as demand goes nuclear

No­var­tis re­cent­ly said that sales of its ra­dio­phar­ma­ceu­ti­cal Plu­vic­to came in low­er than ex­pect­ed in the third quar­ter as a re­sult of man­u­fac­tur­ing is­sues, un­der­scor­ing the ten­sion be­tween the ex­plo­sive growth in the bur­geon­ing mar­ket and the chal­lenges to mak­ing these ra­dio­ther­a­pies.

There were short­ages of Plu­vic­to af­ter “qual­i­ty is­sues” were found at two man­u­fac­tur­ing sites, and the Big Phar­ma had to switch pro­duc­tion to an Ital­ian fa­cil­i­ty and then ship the prod­uct to the US. With short half-lives of the raw ma­te­ri­als, it on­ly had five days to ship the ther­a­py to pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.